125 related articles for article (PubMed ID: 28294055)
1. Therapeutic, Molecular and Computational Aspects of Novel Monoamine Oxidase (MAO) Inhibitors.
Ramesh M; Dokurugu YM; Thompson MD; Soliman ME
Comb Chem High Throughput Screen; 2017; 20(6):492-509. PubMed ID: 28294055
[TBL] [Abstract][Full Text] [Related]
2. Monoamine oxidase B inhibitors based on natural privileged scaffolds: A review of systematically structural modification.
Lv Y; Zheng Z; Liu R; Guo J; Zhang C; Xie Y
Int J Biol Macromol; 2023 Nov; 251():126158. PubMed ID: 37549764
[TBL] [Abstract][Full Text] [Related]
3. Predicting monoamine oxidase inhibitory activity through ligand-based models.
Vilar S; Ferino G; Quezada E; Santana L; Friedman C
Curr Top Med Chem; 2012; 12(20):2258-74. PubMed ID: 23231398
[TBL] [Abstract][Full Text] [Related]
4. Monoamine oxidase: isoforms and inhibitors in Parkinson's disease and depressive illness.
Youdim MB; Bakhle YS
Br J Pharmacol; 2006 Jan; 147 Suppl 1(Suppl 1):S287-96. PubMed ID: 16402116
[TBL] [Abstract][Full Text] [Related]
5. Correlation intensity index-index of ideality of correlation: A hyphenated target function for furtherance of MAO-B inhibitory activity assessment.
Bhawna ; Kumar S; Kumar P; Kumar A
Comput Biol Chem; 2024 Feb; 108():107975. PubMed ID: 37950961
[TBL] [Abstract][Full Text] [Related]
6.
Boulaamane Y; Ibrahim MAA; Britel MR; Maurady A
J Integr Bioinform; 2022 Dec; 19(4):. PubMed ID: 36112816
[TBL] [Abstract][Full Text] [Related]
7. Potent, selective and reversible hMAO-B inhibition by benzalphthalides: Synthesis, enzymatic and cellular evaluations and virtual docking and predictive studies.
Olmo ED; Barboza B; Delgado-Esteban M; Escala N; Jiménez-Blasco D; Lopez-Pérez JL; Cillero de la Fuente L; Quezada E; Munín J; Viña D; Bolaños JP; Feliciano AS
Bioorg Chem; 2024 May; 146():107255. PubMed ID: 38457955
[TBL] [Abstract][Full Text] [Related]
8. Probing the inhibition of MAO-B by chalcones: an integrated approach combining molecular docking, ADME analysis, MD simulation, and MM-PBSA calculations.
Jose J; Varughese JK; Parvez MK; Mathew TV
J Mol Model; 2024 Mar; 30(4):103. PubMed ID: 38478122
[TBL] [Abstract][Full Text] [Related]
9. DFT, ADME studies and evaluation of the binding with HSA and MAO-B inhibitory potential of protoberberine alkaloids from Guatteria friesiana: theoretical insights of promising candidates for the treatment of Parkinson's disease.
Tananta VL; Costa EV; Mary YS; Mary YS; S Al-Otaibi J; Costa RA
J Mol Model; 2023 Nov; 29(11):353. PubMed ID: 37907772
[TBL] [Abstract][Full Text] [Related]
10. A need for clinical trial: re-purposing the Monoamine Oxidase Inhibitors (MAO-I) for rheumatoid arthritis (RA).
Bala A
Inflammopharmacology; 2023 Dec; 31(6):3367-3370. PubMed ID: 37558921
[TBL] [Abstract][Full Text] [Related]
11. Field and atom-based 3D-QSAR models of chromone (1-benzopyran-4-one) derivatives as MAO inhibitors.
Saha M; Gupta S; Dhiman S; Asati V; Ali A; Ali A
J Biomol Struct Dyn; 2023; 41(21):12171-12185. PubMed ID: 36650997
[TBL] [Abstract][Full Text] [Related]
12. Two dimensional-QSAR and molecular dynamics studies of a selected class of aldoxime- and hydroxy-functionalized chalcones as monoamine oxidase-B inhibitors.
Mathew B; Ravichandran V; Raghuraman S; Rangarajan TM; Abdelgawad MA; Ahmad I; Patel HM; Kim H
J Biomol Struct Dyn; 2023 Nov; 41(19):9256-9266. PubMed ID: 36411738
[TBL] [Abstract][Full Text] [Related]
13. The Use of Multiscale Molecular Simulations in Understanding a Relationship between the Structure and Function of Biological Systems of the Brain: The Application to Monoamine Oxidase Enzymes.
Vianello R; Domene C; Mavri J
Front Neurosci; 2016; 10():327. PubMed ID: 27471444
[TBL] [Abstract][Full Text] [Related]
14.
Choudhary D; Kaur R; Rani N; Singh TG; Kumar B
Curr Comput Aided Drug Des; 2024; 20(5):711-722. PubMed ID: 37815181
[TBL] [Abstract][Full Text] [Related]
15. Synthetic cannabinoid receptor agonists are monoamine oxidase-A selective inhibitors.
Hindson SA; Andrews RC; Danson MJ; van der Kamp MW; Manley AE; Sutcliffe OB; Haines TSF; Freeman TP; Scott J; Husbands SM; Blagbrough IS; Anderson JLR; Carbery DR; Pudney CR
FEBS J; 2023 Jun; 290(12):3243-3257. PubMed ID: 36708234
[TBL] [Abstract][Full Text] [Related]
16. Machine learning accelerates pharmacophore-based virtual screening of MAO inhibitors.
Cieślak M; Danel T; Krzysztyńska-Kuleta O; Kalinowska-Tłuścik J
Sci Rep; 2024 Apr; 14(1):8228. PubMed ID: 38589405
[TBL] [Abstract][Full Text] [Related]
17. Filtration of Natural Derivatives as MAO Inhibitors by Virtual Screening: A Potential Lead for Neurodegenerative Disorders.
Malik N; Agnihotri S; Dhiman P
Cent Nerv Syst Agents Med Chem; 2024 Apr; ():. PubMed ID: 38584543
[TBL] [Abstract][Full Text] [Related]
18. Computational Studies Applied to Linalool and Citronellal Derivatives Against Alzheimer's and Parkinson's Disorders: A Review with Experimental Approach.
da Silva PR; de Andrade JC; de Sousa NF; Ribeiro Portela AC; Oliveira Pires HF; Bezerra Remígio MCR; Alves DDN; de Andrade HHN; Dias AL; da Silva Stiebbe Salvadori MG; de Oliveira Golzio AMF; de Castro RD; Scotti MT; Bezerra Felipe CF; de Almeida RN; Scotti L
Curr Neuropharmacol; 2023; 21(4):842-866. PubMed ID: 36809939
[TBL] [Abstract][Full Text] [Related]
19. Molecular Docking and Prediction of Pharmacokinetic Properties of Dual Mechanism Drugs that Block MAO-B and Adenosine A(2A) Receptors for the Treatment of Parkinson's Disease.
Azam F; Madi AM; Ali HI
J Young Pharm; 2012 Jul; 4(3):184-92. PubMed ID: 23112538
[TBL] [Abstract][Full Text] [Related]
20. Piperidine: A Versatile Heterocyclic Ring for Developing Monoamine Oxidase Inhibitors.
Jayan J; Chandran N; Thekkantavida AC; Abdelgawad MA; Ghoneim MM; Shaker ME; Uniyal P; Benny F; Zachariah SM; Kumar S; Kim H; Mathew B
ACS Omega; 2023 Oct; 8(41):37731-37751. PubMed ID: 37867639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
